Works matching IS 1470269X AND DT 2010 AND VI 10 AND IP 1

Results: 9

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 62, doi. 10.1038/tpj.2009.41

By:

Cizmarikova, M.;
Wagnerova, M.;
Schonova, L.;
Habalova, V.;
Kohut, A;
Linkova, A.;
Sarissky, M.;
Mojzis, J.;
Mirossay, L.;
Mirossay, A.

Publication type:

Article

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 54, doi. 10.1038/tpj.2009.45

By:

Khrunin, A. V.;
Moisseev, A.;
Gorbunova, V.;
Limborska, S.

Publication type:

Article

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 20, doi. 10.1038/tpj.2009.32

By:

Laika, B.;
Leucht, S.;
Heres, S.;
Schneider, H.;
Steimer, W.

Publication type:

Article

eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 40, doi. 10.1038/tpj.2009.38

By:

Sandrim, V. C.;
Palei, A. C. T.;
Luizon, M. R.;
Izidoro-Toledo, T. C.;
Cavalli, R. C.;
Tanus-Santos, J. E.

Publication type:

Article

Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 12, doi. 10.1038/tpj.2009.52

By:

Kolev, M. V.;
Tediose, T.;
Sivasankar, B.;
Harris, C. L.;
Thome, J.;
Morgan, B. P.;
Donev, R. M.

Publication type:

Article

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 1, doi. 10.1038/tpj.2009.54

By:

Romaine, S. P. R.;
Bailey, K. M.;
Hall, A. S.;
Balmforth, A. J.

Publication type:

Article

Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 46, doi. 10.1038/tpj.2009.39

By:

Wu, C.-K.;
Luo, J.-L.;
Tsai, C.-T.;
Huang, Y.-T.;
Cheng, C.-L.;
Lee, J.-K.;
Lin, L.-Y.;
Lin, J.-W.;
Hwang, J.-J.;
Chiang, F.-T.

Publication type:

Article

An inosine 5′-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 70, doi. 10.1038/tpj.2009.43

By:

Winnicki, W.;
Weigel, G.;
Sunder-Plassmann, G.;
Bajari, T.;
Winter, B.;
Herkner, H.;
Sengoelge, G.

Publication type:

Article

ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics.

Published in:

Pharmacogenomics Journal, 2010, v. 10, n. 1, p. 30, doi. 10.1038/tpj.2009.55

By:

Liu, Y.-R.;
Loh, E.-W.;
Lan, T.-H.;
Chen, S.-F.;
Yu, Y.-H.;
Chang, Y.-H.;
Huang, C.-J.;
Hu, T.-M.;
Lin, K.-M.;
Yao, Y.-T.;
Chiu, H.-J.

Publication type:

Article